Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review
Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignan...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2019-10-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | https://www.oncologyreviews.org/index.php/or/article/view/425 |
id |
doaj-ea0a7981f02b47f989cb74de1002fe77 |
---|---|
record_format |
Article |
spelling |
doaj-ea0a7981f02b47f989cb74de1002fe772020-11-25T02:47:41ZengPAGEPress PublicationsOncology Reviews1970-55571970-55652019-10-0113210.4081/oncol.2019.425Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic reviewGilbert Lazarus0Jessica Audrey1Anthony William Brian Iskandar2Faculty of Medicine, Universitas IndonesiaFaculty of Medicine, Universitas IndonesiaFaculty of Medicine, Universitas Indonesia Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignancies and may serve as potential therapies for TNBC. This systematic review aims to evaluate the efficacy and safety profiles of PD-1/PD-L1 inhibitors in the treatment of TNBC. Literature search was performed via PubMed, EBSCOhost, Scopus, and CENTRAL databases, selecting studies which evaluated the use of anti-PD-1/PD-L1 for TNBC from inception until February 2019. Risk of bias was assessed by the Newcastle-Ottawa Scale (NOS). Overall, 7 studies evaluating outcomes of 1395 patients with TNBC were included in this systematic review. Anti-PD-1/PD-L1 showed significant antitumor effect, proven by their promising response (objective response rate (ORR), 18.5-39.4%) and survival rates (median overall survival (OS), 9.2-21.3 months). Moreover, anti-PD-1/PD-L1 yielded better outcomes when given as first-line therapy, and overexpression of PD-L1 in tumors showed better therapeutic effects. On the other hands, safety profiles were similar across agents and generally acceptable, with grade ≥3 treatment-related adverse effects (AEs) ranging from 9.5% to 15.6% and no new AEs were experienced by TNBC patients. Most grade ≥3 AEs are immune-mediated, which are manifested as neutropenia, fatigue, peripheral neuropathy, and anemia. PD-1/PD-L1 inhibitors showed promising efficacy and tolerable AEs, and thus may benefit TNBC patients. Further studies of randomized controlled trials with larger populations are needed to better confirm the potential of these agents. https://www.oncologyreviews.org/index.php/or/article/view/425Checkpoint inhibitorprogrammed cell death-1programmed cell death-ligand 1triple-negative breast cancer. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gilbert Lazarus Jessica Audrey Anthony William Brian Iskandar |
spellingShingle |
Gilbert Lazarus Jessica Audrey Anthony William Brian Iskandar Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review Oncology Reviews Checkpoint inhibitor programmed cell death-1 programmed cell death-ligand 1 triple-negative breast cancer. |
author_facet |
Gilbert Lazarus Jessica Audrey Anthony William Brian Iskandar |
author_sort |
Gilbert Lazarus |
title |
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review |
title_short |
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review |
title_full |
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review |
title_fullStr |
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review |
title_full_unstemmed |
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review |
title_sort |
efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: a comprehensive systematic review |
publisher |
PAGEPress Publications |
series |
Oncology Reviews |
issn |
1970-5557 1970-5565 |
publishDate |
2019-10-01 |
description |
Triple-negative breast cancer (TNBC) is associated with worse prognosis, with limited treatment regiments available and higher mortality rate. Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) showed great potentials in treating malignancies and may serve as potential therapies for TNBC. This systematic review aims to evaluate the efficacy and safety profiles of PD-1/PD-L1 inhibitors in the treatment of TNBC. Literature search was performed via PubMed, EBSCOhost, Scopus, and CENTRAL databases, selecting studies which evaluated the use of anti-PD-1/PD-L1 for TNBC from inception until February 2019. Risk of bias was assessed by the Newcastle-Ottawa Scale (NOS). Overall, 7 studies evaluating outcomes of 1395 patients with TNBC were included in this systematic review. Anti-PD-1/PD-L1 showed significant antitumor effect, proven by their promising response (objective response rate (ORR), 18.5-39.4%) and survival rates (median overall survival (OS), 9.2-21.3 months). Moreover, anti-PD-1/PD-L1 yielded better outcomes when given as first-line therapy, and overexpression of PD-L1 in tumors showed better therapeutic effects. On the other hands, safety profiles were similar across agents and generally acceptable, with grade ≥3 treatment-related adverse effects (AEs) ranging from 9.5% to 15.6% and no new AEs were experienced by TNBC patients. Most grade ≥3 AEs are immune-mediated, which are manifested as neutropenia, fatigue, peripheral neuropathy, and anemia. PD-1/PD-L1 inhibitors showed promising efficacy and tolerable AEs, and thus may benefit TNBC patients. Further studies of randomized controlled trials with larger populations are needed to better confirm the potential of these agents.
|
topic |
Checkpoint inhibitor programmed cell death-1 programmed cell death-ligand 1 triple-negative breast cancer. |
url |
https://www.oncologyreviews.org/index.php/or/article/view/425 |
work_keys_str_mv |
AT gilbertlazarus efficacyandsafetyprofilesofprogrammedcelldeath1programmedcelldeathligand1inhibitorsinthetreatmentoftriplenegativebreastcanceracomprehensivesystematicreview AT jessicaaudrey efficacyandsafetyprofilesofprogrammedcelldeath1programmedcelldeathligand1inhibitorsinthetreatmentoftriplenegativebreastcanceracomprehensivesystematicreview AT anthonywilliambrianiskandar efficacyandsafetyprofilesofprogrammedcelldeath1programmedcelldeathligand1inhibitorsinthetreatmentoftriplenegativebreastcanceracomprehensivesystematicreview |
_version_ |
1724752021822636032 |